Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odanacatib in castration-resistant prostate cancer
NCT00691899Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Primary completion
- Sep 2008
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of odanacatib in castration-resistant prostate cancer (CRPC), sponsored by Merck & Co.. Planned start Sep 2008; status: withdrawn.
02
Drugs
odanacatib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00691899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00691899.